Dementia is considered as a condition where a person suffers from a mere decline in mental capacity to a serious enough loss, that can reduce quality of life. Memory loss is one example.

Dementia does not concern specific diseases. It is a set of symptoms related to memory loss or other thinking skills severe enough to reduce a person’s ability to perform daily activities. Alzheimer’s disease accounts for 60-80% of cases. Vascular dementia, which occurs after a stroke, is the second most common type of dementia. But there are many other conditions that can cause dementia, including some that are reversible, such as thyroid problems and vitamin deficiencies. The various forms of dementia are often generally and clearly misidentified as “old” or “senile dementia”, which reflects the former widespread but erroneous belief that severe spiritual decline is a normal part of aging.


Diagnosis of Real Causes & Treatment of Dementia

  • Gradual restoration of cellular function
  • Personalized therapeutic protocols, without chemical residues and excipients
  • Treating the real causes
  • Therapeutic formulas that work alone or in combination with any other medication
  • Adopting a Molecular / Therapeutic Nutrition Plan


Scientific Evidence

The epidemiology of dementia does indeed reveal that these diseases have reached epidemic proportions and cause a serious public health problem. They occur in about 6% of people over 65 years of age and are highly age-dependent. In the 65-69 age group, there are more than two new cases per 1000 people each year. This number is increasing almost exponentially with increasing age  from the age of 90, out of 1000 people, 70 new cases of dementia are expected annually.


Memory loss and other dementia symptoms

While symptoms of dementia can vary widely, at least two of the following basic spiritual functions must be significantly attenuated in order for individuals to be considered ill. These can be: memory, communication and language, focus and attention, critical ability, visual perception.


Causes of dementia

Dementia is caused by damage to the brain cells. These lesions impede the ability of brain cells to communicate with one another. When brain cells cannot communicate properly, thinking, behavior, and emotions can be affected. The main difference between age-related memory loss and dementia is that memory loss has little effect on daily performance and abilities, while dementia, on the other hand, is characterized by a persistent, neurodegenerative process affecting two or more mental faculties such as memory, language, judgment and abstract thinking. Some causes of dementia-like dementia or symptoms can be reversed with treatment. These include:

  • Infections and disorders of the immune system.
  • Metabolic problems and endocrine abnormalities.
  • Eating deficiencies.
  • Side effects of medicines.
  • Subcutaneous hematomas.
  • Heavy metal poisoning, such as lead


Types of dementia

Different types of dementia relate to specific types of brain cell damage in specific areas of the brain. For example, in Alzheimer’s disease, high levels of certain proteins inside and outside the brain cells make it difficult for the brain cells to stay healthy and communicate with one another. The brain region called the hippocampus is the center of learning and memory in the brain, and the brain cells in that region are often the first to be damaged. That is why memory loss is often one of the first symptoms of Alzheimer’s disease.

While most dementia-induced brain changes are permanent and worsen over time, thought and memory problems caused by depression, drug side effects, alcohol overuse, thyroid problems, vitamin deficiency can be improved when the exact cause is addressed or identified.


How is it treated so far?

The drugs used to date help the brain’s memory system improve its functioning. They consist of 2 categories:

  • acetylcholinesterase inhibitors (donepezil, ribastigmine, galantamine)
  • NMDA receptor inhibitors (the memantine)

These substances improve mental functioning in 2/3 of patients up to 12 months. They also improve the psychiatric symptoms and behavioral disorders as well as the functionality of the individual. Medications that improve other symptoms (eg, antidepressants if depressed, depressant in anxiety) or are used to treat, for example, correction of abnormalities in sodium, calcium, thyroxine administration, hypothyroidism or neovascularization, subdural hematoma.


Genetic predisposition to dementia

Some risk factors, such as age and genetics, cannot be changed. However, researchers continue to investigate the effect of other risk factors on brain health and prevention of dementia. Some of the most active research areas for risk reduction and prevention include cardiovascular factors, fitness and nutrition.

It is not just a gene, but the interaction between many genes and the environment that puts one at risk for chronic diseases, such as dementia. Also we know that many factors affect the function of genes such as nutrition, vitamins and minerals, toxins, allergens, stress, lack of sleep and exercise and much more. A complete gland mapping is capable of identifying the responsible genes for the disease. Early diagnosis can cure reversible causes of memory loss, reduce dementia or improve the quality of life of people with Alzheimer’s disease or other forms of Alzheimer’s disease.


The new medical reality

Restoring proper thyroid function, treating mercury toxicity, treating chronic inflammation and deficiencies in vitamins B6 and D, folic acid, coenzyme Q10 and omega-3 fatty acids, natural hormone or natural hormones guidance greatly helps improve cognitive function and prevent dementia. Dementia in modern medical reality can be reversed by monitoring all the factors that affect the function of the brain, with proper genetic compliance with all the conditions of the body to work in a balanced and nutrient-rich manner.




Dr. Nikoleta Koini, M.D.

Doctor of Functional, Preventive, Anti-ageing and Restorative Medicine.
Diplomate and Board Certified in Anti-aging, Preventive, Functional and Regenerative Medicine from A4M (American Academy in Antiaging Medicine).


Read More

Functional Med System

Biochemical, Molecular and Genetic Approach Exams



  • National Institute of Environmental Health Sciences. Neurodegenerative diseases. Reviewed September 10, 2019. Accessed May 18, 2020. https://www.niehs.nih.gov/research/supported/health/neurodegenerative/index.cfm
  • Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer’s disease. J Alzheimers Dis.2018;62(3):1403-1416. doi:10.3233/JAD-170585
  • García S, Martín Giménez VM, Mocayar Marón FJ, Reiter RJ, Manucha W. Melatonin and cannabinoids: mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases. Histol Histopathol. 2020:18212. doi:10.14670/HH-18-212
  • Alzheimer’s Association. Alternative treatments. Accessed May 18, 2020. https://www.alz.org/alzheimers-dementia/treatments/alternative-treatments
  • Parkinson’s Foundation. Over the counter and complementary therapies. Accessed May 18, 2020. https://www.parkinson.org/Understanding-Parkinsons/Treatment/Over-the-Counter-and-Complementary-Therapies
  • National Multiple Sclerosis Society. Complementary and alternative medicines. Accessed May 18, 2020. https://www.nationalmssociety.org/Treating-MS/Complementary-Alternative-Medicines
  • Wesselman LMP, Doorduijn AS, de Leeuw FA, et al. Dietary patterns are related to clinical characteristics in memory clinic patients with subjective cognitive decline: the SCIENCe project. Nutrients. 2019;11(5):1057.doi:10.3390/nu11051057
  • Fieldhouse JLP, Doorduijn AS, de Leeuw FA, et al. A suboptimal diet is associated with poorer cognition: the NUDAD project. Nutrients. 2020;12(3):703. doi:10.3390/nu12030703
  • Nolan JM, Mulcahy R, Power R, Moran R, Howard AN. Nutritional intervention to prevent Alzheimer’s disease: potential benefits of xanthophyll carotenoids and omega-3 fatty acids combined. J Alzheimers Dis. 2018;64(2):367-378. doi:10.3233/JAD-180160
  • Calil SRB, Brucki SMD, Nitrini R, Yassuda MS. Adherence to the Mediterranean and MIND diets is associated with better cognition in healthy seniors but not in MCI or AD. Clin Nutr ESPEN. 2018;28:201-207. doi:10.1016/j.clnesp.2018.08.001
  • Power R, Prado-Cabrero A, Mulcahy R, Howard A, Nolan JM. The role of nutrition for the aging population: implications for cognition and Alzheimer’s disease. Annu Rev Food Sci Technol. 2019;10:619-639.doi:1146/annurev-food-030216-030125
  • Chai B, Gao F, Wu R, et al. Vitamin D deficiency as a risk factor for dementia and Alzheimer’s disease: anupdated meta-analysis. BMC Neurol. 2019;19(1):284. doi:10.1186/s12883-019-1500-6
  • Bianchi VE, Herrera PF, Laura R. Effect of nutrition on neurodegenerative diseases. A systematic review.Nutr Neurosci. Published online November 4, 2019. doi:10.1080/1028415X.2019.1681088
  • Grodzicki W, Dziendzikowska K. The role of selected bioactive compounds in the prevention of Alzheimer’s disease. Antioxidants. 2020;9(3):229. doi:10.3390/antiox9030229
  • AlAmmar WA, Albeesh FH, Ibrahim LM, Algindan YY, Yamani LZ, Khattab RY. Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review. Nutr Neurosci. Published online August 28, 2019. doi:10.1080/1028415X.2019.1659560
  • Wlodarek D. Role of ketogenic diets in neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). Nutrients. 2019;11(1):169. doi:10.3390/nu11010169
  • Chauhan A, Chauhan V. Beneficial effects of walnuts on cognition and brain health. Nutrients. 2020;12(2):550. doi:10.3390/nu12020550
  • Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean diet and age-related cognitive decline: a randomized clinical trial. JAMA Intern Med. 2015;175(7):1094-1103. doi:10.1001/jamainternmed.2015.1668
  • Meng X, Zhou J, Zhao CN, Gan RY, Li HB. Health benefits and molecular mechanisms of resveratrol: a narrative review. Foods. 2020;9(3):340. doi:10.3390/foods9030340
  • Huhn S, Beyer F, Zhang R, et al. Effects of resveratrol on memory performance, hippocampus connectivity and microstructure in older adults – a randomized controlled trial. Neuroimage. 2018;174:177-190. doi:10.1016/j.neuroimage.2018.03.023
  • Evans HM, Howe PR, Wong RH. Effects of resveratrol on cognitive performance, mood and cerebrovascular function in post-menopausal women: a 14-week randomised placebo-controlled intervention trial. Nutrients. 2017;9(1):27. doi:10.3390/nu9010027
  • Liu H, Ye M, Guo H. An updated review of randomized clinical trials testing the improvement of cognitive function of Ginkgo biloba extract in healthy people and Alzheimer’s patients. Front Pharmacol. 2020;10:1688. doi:10.3389/fphar.2019.01688
  • Power R, Coen RF, Beatty S, et al. Supplemental retinal carotenoids enhance memory in healthy individuals with low levels of macular pigment in a randomized, double-blind, placebo-controlled clinical trial. J Alzheimers Dis. 2018;61(3):947-961. doi:10.3233/JAD-170713
  • Lee DH, Chon J, Kim Y, et al. Association between vitamin D deficiency and cognitive function in the elderly Korean population: a Korean frailty and aging cohort study. Medicine (Baltimore). 2020;99(8):e19293. doi:10.1097/MD.0000000000019293
  • Feige J, Moser T, Bieler L, Schwenker K, Hauer L, Sellner J. Vitamin D supplementation in multiple sclerosis: a critical analysis of potentials and threats. Nutrients. 2020;12(3):783. doi:10.3390/nu12030783
  • Kouchaki E, Afarini M, Abolhassani J, et al. High-dose ?-3 fatty acid plus vitamin D3 supplementation affects clinical symptoms and metabolic status of patients with multiple sclerosis: a randomized controlled clinical trial. J Nutr. 2018;148(8):1380-1386. doi:10.1093/jn/nxy116
  • Martínez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318-1325. doi:10.1136/jnnp-2012-304792
  • Lee JE, Bisht B, Hall MJ, et al. A multimodal, nonpharmacologic intervention improves mood and cognitive function in people with multiple sclerosis. J Am Coll Nutr. 2017;36(3):150-168. doi:10.1080/07315724.2016.1255160
  • Ota M, Matsuo J, Ishida I, et al. Effects of a medium-chain triglyceride-based ketogenic formula on cognitive function in patients with mild-to-moderate Alzheimer’s disease. Neurosci Lett. 2019;690:232-236. doi: 10.1016/j.neulet.2018.10.048